Aiforia Technologies Plc, Company release, 14 October 2022, 10:30 a.m. EEST. Aiforia Technologies Plc reinforces its Management Team to accelerate the implementation of the company's growth strategy.

Thomas Westerling-Bui has, as of October 14th 2022, been appointed as Chief Commercial Officer of Americas and as a member of the Management Team (previously Vice President of AI Solutions & Strategy). Thomas joined Aiforia in 2018 and has been instrumental in establishing the US subsidiary and strengthening Aiforia's position in the market.

Thomas received his Ph.D. with honors from the University of Helsinki Medical School. He went on to do research, supported by an EMBO long-term fellowship at the Dana Farber Cancer Institute and Harvard Medical School in Boston. His fellowship focused on understanding the effects of epigenetic and genomic factors on breast cancer,  prostate cancer, and drug resistance. Thomas was accepted into the MIT Sloan Executive MBA program in 2022. 

"We are very pleased to see the management team bolstered by Thomas's unique talent. Thomas has not only a very strong background in pathology and a deep understanding of our customers' needs, but is also experienced in commercial leadership. Thomas together with the global team has earned us significant customers both in the diagnostics and pharmaceutical drug development industries, such as Mayo Clinic, MIT, and Boehringer Ingelheim. We have strengthened our US science and sales organization in seven states, and now Thomas has the perfect opportunity to further the conquest of the American market as a commercial leader," says Jukka Tapaninen, CEO of Aiforia Technologies Plc.

After the appointment, the composition of Aiforia's Management Team is as follows:
 

Jukka Tapaninen, Chief Executive Officer

Kaisa Helminen, Chief Operating Officer

Veli-Matti Parkkonen, Chief Financial Officer

Kari Pitkänen, Director of Business Development 

Tuomas Ropponen, Chief Technology Officer

Thomas Westerling-Bui, Chief Commercial Officer, Americas


More detailed information on the members of the Management Team is available on the company's website at https://investors.aiforia.com/management-team.

Further inquiries 
 
Jukka Tapaninen, CEO, Aiforia Technologies Plc, tel. +33 61 041 6686
https://investors.aiforia.com/
 
Certified Adviser 
 
UB Securities Ltd, tel. +358 9 25 380 225  
 
About Aiforia 
 
Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep-learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud-based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more. Find out more at www.aiforia.com 

https://news.cision.com/aiforia-technologies-oyj/r/change-in-aiforia-technologies-plc-s-management-team,c3648093

https://mb.cision.com/Main/20889/3648093/1638438.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English